Lundbeck and Proximagen Sign Strategic Partnership Agreement

Lundbeck and Proximagen Sign Strategic Partnership Agreement

Lundbeck to make equity investment of £10.3 million in Proximagen at 180 pence per share

alby, Denmark and London, UK, 29 September 2011 - H. Lundbeck A/S ("Lundbeck"), the international pharmaceutical company and a world leader in treating central nervous system ("CNS") disorders and Proximagen Group plc ("Proximagen"), the rapidly growing company also with a focus on the treatment of disorders of the CNS, today announce that they have entered into a Strategic Partnership Agreement (the "Agreement").

The Agreement is designed to formalise a partnership between the two companies, a partnership in which Lundbeck and Proximagen will jointly apply their expertise in CNS drug development towards achieving their collective strategic and growth objectives.

As part of the Agreement, a steering committee involving experts from both companies will focus on developing three of Proximagen's programmes, with the aim of identifying novel innovative therapies for serious diseases such as epilepsy, pain and inflammatory disorders. Lundbeck will also receive certain negotiation rights in relation to these programmes.

Under the terms of the Agreement, Proximagen will issue 5,738,100 new ordinary 1p shares ("New Shares") to Lundbeck at a price of 180p per New Share. The total consideration paid for the New Shares will be £10,328,580. The subscription price of 180p represents a premium of 36% over the average daily closing price of Proximagen's shares in the six month period from 29 March 2011 to 28 September 2011.

Anders Gersel Pedersen, Lundbeck's Executive Vice President for Research and Development, said: "We are very pleased to be working with Proximagen and its experienced scientific and management team. Proximagen has built an exciting pipeline which offers real promise in treating a number of CNS disorders. This strategic partnership will provide Lundbeck with exposure to some very exciting research programmes."

Proximagen's Chief Executive Officer, Kenneth Mulvany, said: "We are delighted to have Lundbeck, one of the most respected pharmaceutical companies in the CNS field, as a strategic shareholder in Proximagen. Acquiring and developing high quality assets, mitigating risk and building closer relationships with Big Pharma are three of our strategic priorities. The partnership with Lundbeck validates our strategy and represents a major step forward in realising the value of key compounds in our pipeline. We look forward to working closely with Lundbeck as we each share our expertise to develop therapies for patients."

Ends

Enquiries: Proximagen Group plc Tel: +44 (0)20 7400 7700 Kenneth Mulvany, Chief Executive Officer James Hunter, Finance Director H.Lundbeck A/S Tel: +45 36 43 24 26 Palle Holm Olesen, Chief Specialist, Investor Relations [email protected] Mads Kronborg, Media Relations Manager [email protected] Singer Capital Markets (Nominated Adviser for Proximagen) Tel: +44 (0)20 3205 7500 Shaun Dobson / Claes Spång M:Communications (Media enquiries for Proximagen) Tel: +44 (0)20 7920 2330 Mary Clark / Peter Laing / Emma Thompson [email protected]

About Proximagen Proximagen Group plc (AIM:PRX) is focused on the development and commercialisation of novel therapeutics primarily for diseases of the central nervous system. The Company is developing a broad pipeline of drug candidate programmes and has plans for substantial future growth through a strategy of acquisition and consolidation of innovative drug candidate programmes in its core disease areas. Proximagen believes that significant value creation opportunities can arise by building critical mass, reducing the cost base, and focusing resources on a more promising pipeline where tough decisions will be taken to discontinue weak programmes. Proximagen strives for true scientific innovations that break new ground in treatment. Using this standard as a development benchmark makes things more challenging, but demonstrates the Company's commitment to pursuing only those opportunities that improve upon current therapies in meaningful ways and represent the best chance of generating significant commercial value. For more information, please visit the Company's website at www.proximagen.com. About Lundbeck H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases. Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2010, the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com.

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.